Atypical antipsychotic: Difference between revisions
Rickjpelleg (talk | contribs) m Unlinked: Involuntary using Dab solver |
Debate |
||
| Line 4: | Line 4: | ||
Both generations of medication tend to block receptors in the brain's [[dopamine pathways]], but atypicals differ from [[typical antipsychotic]]s in that they are less likely to cause [[extrapyramidal symptom|extrapyramidal]] [[motor control]] [[disabilities]] in patients, which include unsteady [[Parkinson's disease]]-type movements, body [[Rigidity (neurology)|rigidity]] and involuntary [[tremor]]s.<ref>Culpepper, L. (2007) A Roadmap to Key Pharmacologic Principles in Using Antipsychotics, Primary Care Companion To The Journal of Association of Medicine and Psychiatry 9(6) 444-454 Retrieved from http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2139919/</ref> These abnormal body movements can become permanent even after medication is stopped. |
Both generations of medication tend to block receptors in the brain's [[dopamine pathways]], but atypicals differ from [[typical antipsychotic]]s in that they are less likely to cause [[extrapyramidal symptom|extrapyramidal]] [[motor control]] [[disabilities]] in patients, which include unsteady [[Parkinson's disease]]-type movements, body [[Rigidity (neurology)|rigidity]] and involuntary [[tremor]]s.<ref>Culpepper, L. (2007) A Roadmap to Key Pharmacologic Principles in Using Antipsychotics, Primary Care Companion To The Journal of Association of Medicine and Psychiatry 9(6) 444-454 Retrieved from http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2139919/</ref> These abnormal body movements can become permanent even after medication is stopped. |
||
During the course of treatment atypical antipsychotics are associated with the following benefits; higher rate of responders, efficiency in patients with refractory disease, lower risk of suicides, better functional capacity and an improved quality of life.<ref name="Horacek, J. 2006"/> |
During the course of treatment atypical antipsychotics are associated with the following benefits; higher rate of responders, efficiency in patients with refractory disease, lower risk of suicides, better functional capacity and an improved quality of life.<ref name="Horacek, J. 2006"/> However, there has been considerable debate about whether second-generation antipsychotic drugs are better than first-generation antipsychotic drugs.<ref name=leucht/> |
||
== List of atypical antipsychotics == |
== List of atypical antipsychotics == |
||
| Line 83: | Line 83: | ||
A study by Sernyak and colleagues found that the prevalence of diabetes in atypical antipsychotic treatments was statistically significantly higher than that of conventional treatment <ref name="ncbi.nlm.nih.gov"/>. The authors of this study suggest that it is a causal relationship the Kabinoff et al. suggest the findings only suggest a temporal association <ref name="ncbi.nlm.nih.gov"/>. Kabinoff et al. suggest that there is insufficient data from large studies to demonstrate a consistent or significant difference in the risk of insulin resistance during treatment with various atypical antipsychotics <ref name="ncbi.nlm.nih.gov"/>. |
A study by Sernyak and colleagues found that the prevalence of diabetes in atypical antipsychotic treatments was statistically significantly higher than that of conventional treatment <ref name="ncbi.nlm.nih.gov"/>. The authors of this study suggest that it is a causal relationship the Kabinoff et al. suggest the findings only suggest a temporal association <ref name="ncbi.nlm.nih.gov"/>. Kabinoff et al. suggest that there is insufficient data from large studies to demonstrate a consistent or significant difference in the risk of insulin resistance during treatment with various atypical antipsychotics <ref name="ncbi.nlm.nih.gov"/>. |
||
==Debate== |
|||
There has been considerable debate about whether second-generation antipsychotic drugs are better than first-generation |
|||
antipsychotic drugs.<ref name=leucht>{{cite web |url=http://ectweb.pbworks.com/f/Second-generation+versus+first-generation+antipsychotic+drugs+for+schizophrenia+a+meta-analysis.pdf |title=Second-generation versus first-generation antipsychotic drugs for schizophrenia: a meta-analysis |author=Stefan Leucht, Caroline Corves, Dieter Arbter, Rolf R Engel, Chunbo Li, John M Davis |date=January 3, 2009 |work=Lancet |page=31–41 }}</ref> It has been suggested that there is no validity to the term second-generation antipsychotic drugs and that the drugs that currently occupy this category are not identical to each other in mechanism, efficacy, and side-effect profiles: |
|||
<blockquote> |
|||
...the second-generation drugs have no special atypical characteristics that separate them from the typical, or first-generation, antipsychotics. As a |
|||
group they are no more efficacious, do not improve specific symptoms, have no clearly different side-effect profiles than the first-generation antipsychotics, and are less cost effective. The spurious invention of the atypicals can now be regarded as invention only, cleverly manipulated by the drug industry for marketing purposes and only now being exposed.<ref>{{cite web |url=http://psychrights.org/research/Digest/NLPs/SpuriousAdvanceofNeurolepticsLancetTurner2008.pdf |title=The spurious advance of antipsychotic drug therapy |author=Peter Tyrer and Tim Kendall |date=January 3, 2009 |work=Lancet |Vol= 373 }}</ref> |
|||
</blockquote> |
|||
Robert Whitaker suggests that the "wonder drug" glow around the second generation psychotropics has long since disappeared. He views the "hyping" of the top-selling atypicals as "one of the more embarrassing episodes in psychiatry's history, as one government study after another failed to find that they were any better than the first-generation anti-psychotics".<ref>{{cite web |title=Anatomy of an Epidemic |author=Robert Whitaker |date=2010 |publisher=Crown |page=303 }}</ref> |
|||
== See also == |
== See also == |
||
* [[Antipsychotic]] |
* [[Antipsychotic]] |
||
Revision as of 20:47, 14 March 2011
The atypical antipsychotics (AAP) (also known as second generation antipsychotics) are a group of antipsychotic tranquilizing drugs used to treat psychiatric conditions. Some atypical antipsychotics are FDA approved for use in the treatment of schizophrenia. Some carry FDA approved indications for acute mania, bipolar depression, psychotic agitation, bipolar maintenance, and other indications. Both generations of medication tend to block receptors in the brain's dopamine pathways, but atypicals differ from typical antipsychotics in that they are less likely to cause extrapyramidal motor control disabilities in patients, which include unsteady Parkinson's disease-type movements, body rigidity and involuntary tremors.[1] These abnormal body movements can become permanent even after medication is stopped.
During the course of treatment atypical antipsychotics are associated with the following benefits; higher rate of responders, efficiency in patients with refractory disease, lower risk of suicides, better functional capacity and an improved quality of life.[2] However, there has been considerable debate about whether second-generation antipsychotic drugs are better than first-generation antipsychotic drugs.[3]
List of atypical antipsychotics
The following are approved and marketed in various parts of the world:
|
|
And these are currently under development but are not yet licensed:
- Bifeprunox (DU-127,090)
- Pimavanserin (ACP-103)
- Vabicaserin (SCA-136)
History
The first atypical anti-psychotic medication, clozapine, was discovered in the 1950s, and introduced into clinical practice in the 1970s. Clozapine fell out of favor due to concerns over drug-induced agranulocytosis. With research indicating its effectiveness in treatment-resistant schizophrenia and the development of an adverse event monitoring system, clozapine reemerged as a viable antipsychotic. According to Barker (2003) the three most accepted atypical drugs are; clozapine, risperidone and olanzapine. However, he goes on to explain that clozapine is usually the last resort when other drugs fail. Clozapine can cause agranulocytosis (which is decreased number of white blood cells), Barker (2003) explains that a person on clozapine will have to go through rigorous blood monitoring. Despite the effectiveness of clozapine for treatment-resistant schizophrenia, agents with a more favourable side effect profile were sought after for widespread use. During the 1990s, olanzapine, risperidone and quetiapine were introduced, with ziprasidone and aripiprazole following in the early 2000s. The atypical anti-psychotic paliperidone was approved by the FDA in late 2006.
The atypical anti-psychotics have found favour among clinicians and are now considered to be first line treatments for schizophrenia and are gradually replacing the typical antipsychotics. In the past, most researchers have agreed that the defining characteristic of an atypical antipsychotic is the decreased propensity of these agents to cause extrapyramidal side effects (EPS)[4] and an absence of sustained prolactin elevation.[5]
The terminology can be imprecise. The definition of "atypicality" was based upon the absence of extrapyramidal side effects, but there is now a clear understanding that atypical antipsychotics can still induce these effects (though to a lesser degree than typical antipsychotics.)[6] Recent literature focuses more upon specific pharmacological actions, and less upon categorization of an agent as "typical" or "atypical". There is no clear dividing line between the typical and atypical antipsychotics therefore categorization based on the action is difficult [7].
More recent research is questioning the notion that second generation anti-psychotics are superior to first generation typical anti-psychotics. Using a number of parameters to assess quality of life, Manchester University researchers found that typical anti-psychotics were no worse than atypical anti-psychotics. The research was funded by the National Health Service (NHS) of the UK.[8] Because each medication (whether first or second generation) has its own profile of desirable and adverse effects, a neuropsychopharmacologist may recommend one of the older ("typical" or first generation) or newer ("atypical" or second generation) antipsychotics alone or in combination with other medications, based on the symptom profile, response pattern, and adverse effects history of the individual patient.
Pharmacokinetics
The most common route of administration of AAP is oral [9]. Antipsychotics can also be injected, but this method is not as common [9]. Once the antipsychotics are in the body they are lipid soluble and are readily absorbed from the digestive tract and can easily pass the blood brain barrier and placental barriers [9]. Once in the brain the antipsychotics make their way to the synapse and work at the synapse by binding to the receptor (Culpepper, 2007). Antipsychotics are entirely destroyed by the body's metabolism and the metabolites are excreted in the urine (McKim, 2007). These drugs have relatively long half lives [9]. Each drug has a different half life but the occupancy of the D2 receptor falls off within 24 hours with atypical antipsychotics, while lasting over 24 hours for the typical antipsychotics [7]. This may explain why relapse into psychosis happens quicker with atypical antipsychotics than with typical antipsychotics, as the drug is excreted faster and is no longer working in the brain [7]. Physical dependence with these drugs is very rare, therefore withdrawal symptoms are rarely seen.[9]. Sometimes if AAP are abruptly stopped psychotic symptoms, movement disorders and difficulty in sleep are seen [9]. It is possible that withdrawal is rarely seen is because the AAP are stored in the fat tissues in the body and slowly released[9]).
Pharmacology
The mechanism of action of these agents is unknown, and differs greatly from drug to drug. The variation in the receptor binding profile is such that the only effect all have in common is an anti-psychotic effect; the side effect profiles vary tremendously. It is not clear the mechanisms behind atypical antipsychotic action. All antipsychotics work on the dopamine system but all vary in regards to the affinity to the dopamine receptors [2]. There are 5 types of dopamine receptors in humans [7]. There are the “D1-like” group which are types 1 and 5 which are similar in structure and drug sensitivity [7]. The “D2-like” group includes dopamine receptors 2, 3 and 4 and have a very similar structure but very different sensitivities to antipsychotic drugs [7].
The “D1-like” receptors have been found to not be clinically relevant in therapeutic action [7]. If D1 receptors were a critical component of the mechanism of AAP blocking just the D1 receptor would improve the psychiatric symptoms that are exhibited [7]. If D1 receptor binding was a critical component of the action of antipsychotics they would need to be present in maintenance dosages [7]. This is not seen. They are not present or present in low or negligible levels which would is not even to maintain the elimination of the symptoms that are seen [7].
The “D2-like” group of dopamine receptors are classified together based on structure but not drug sensitivity. It has been shown that D2 receptor blockade is necessary for action [2]. All antipsychotics block D2 receptors to some degree, but the affinity of the antipsychotics vary from drug to drug and it has been hypothesized that it is the varying in affinities that causes a change in effectiveness (Horacek et al., 2002).
One theory for how atypicals work is the “fast-off” theory [7]. This theory of antipsychotic action is that AAP have low affinities for the D2 receptor and only bind loosely to the receptor and rapidly released [7]. In fact the AAP bind more loosely to the D2 receptor than dopamine itself [7]. Because the AAP effectively interfere with the phasic release of endogenous dopamine [2]. The AAP transiently bind and rapidly dissociate to the D2 receptor to allow normal dopamine transmission [10]. It is this transient binding that that keeps prolactin levels normal, spares cognition and obviates EPS [7].
From a historical point of view there has been interest in the role of serotonin and treatment with the use antipsychotics [7]. Experience with LSD suggests that 5-HT2A receptor blockade may be a promising method of treating schizophrenia [7]. One problem with this is the fact that psychotic symptoms caused by 5-HT2 receptor agonists differs substantially from the symptoms of schizophrenic psychoses [7]. One promising factor of this is where the 5-HT2A receptors are located in the brain. They are localized on hippocampal and cortical pyramidal cells and have a high density in the fifth neocortex layer where the inputs of various cortical and subcortical brain areas are integrated [7]. This makes the blocking of this receptor an interesting area considering these areas in the brain are of interest in the development of schizophrenia [10]. This is an area of research that could prove convincing but has not yielded any convincing results [7]. Evidence points to the fact that serotonin is not sufficient to produce an antipsychotic effect but serotonergic activity in combination with D2 receptor blockade may be responsible [7]. Regardless of the neurotransmitters these AAP have an effect on antipsychotic drugs appear to work by inducing restructuring of neuronal networks [7]. They are able to induce these structural changes.
Side effects
The side effects reportedly associated with the various atypical antipsychotics vary and are medication-specific. Generally speaking, atypical antipsychotics are hoped to have a lower likelihood for the development of tardive dyskinesia than the typical antipsychotics. However, tardive dyskinesia typically develops after long term (possibly decades) use of antipsychotics. It is not clear, then, if atypical antipsychotics, having been in use for a relatively short time, produce a lower incidence of tardive dyskinesia.
Akathisia is more likely to be less intense with these drugs than the typical antipsychotics [citation needed] although many patients would dispute this claim. In 2004, the Committee for the Safety of Medicines (CSM) in the UK issued a warning that olanzapine and risperidone should not be given to elderly patients with dementia, because of an increased risk of stroke. Sometimes atypical antipsychotics can cause abnormal shifts in sleep patterns, and extreme tiredness and weakness.
In 2006, USA Today published an article about the effects of antipsychotic medication in children. None of the atypicals (Clozaril, Risperdal, Zyprexa, Seroquel, Abilify and Geodon) have been approved for children, and there is little research on their effects on children. From 2000–2004, there were 45 reported deaths in which an atypical antipsychotic was listed as the "primary suspect." There were also 1328 reports of serious, and sometimes life threatening, side effects. These include tardive dyskinesia (involuntary jerking and facial grimacing) and dystonia (involuntary muscle contractions that can interfere with talking and eating).
Some of the other side effects that have been suggested is that atypical antipsychotics increase the risk of cardiovascular disease [11]. The research that Kabinoff et al., evaluated fount that the increase in cardiovascular disease is seen regardless of the treatment they receive, instead it is caused by many different factors such as lifestyle or diet [11].
Sexual side effects have also been reported when taking atypical antipsychotics [12]. In males antipsychotics reduce sexual interest, impair sexual performance with the main difficulties being failure to ejaculate [9]. In females there may be abnormal menstrual cycles and infertility [13]. In both males and females the breasts may become enlarged and a fluid will sometimes ooze from the nipples [9].
Tardive dyskinesia
All of the atypical antipsychotics warn about the possibility of tardive dyskinesia in their package inserts and in the PDR. It is not possible to truly know the risks of tardive dyskinesia when taking atypicals, because tardive dyskinesia can take many decades to develop and the atypical antipsychotics are not old enough to have been tested over a long enough period of time to determine all of the long-term risks. One hypothesis as to why atypicals have a lower risk of tardive dyskinesia is because they are much less fat-soluble than the typical antipsychotics and because they are readily released from D2 receptor and brain tissue [7]. The typical antipsychotics remain attached to the D2 receptors and accumulate in the brain tissue which may lead to TD [7].
Metabolism
Recently, metabolic concerns have been of grave concern to clinicians, patients and the FDA. In 2003, the Food and Drug Administration (FDA) required all manufacturers of atypical antipsychotics to change their labeling to include a warning about the risks of hyperglycemia and diabetes with atypical antipsychotics. It must also be pointed out that although all atypicals must carry the warning on their labeling, some evidence shows that atypicals are not equal in their effects on weight and insulin sensitivity.[14] The general consensus is that clozapine and olanzapine are associated with the greatest effects on weight gain and decreased insulin sensitivity, followed by risperidone and quetiapine.[14] Ziprasidone and aripiprazole are thought to have the smallest effects on weight and insulin resistance, but clinical experience with these newer agents is not as developed as that with the older agents.[14]
A study by Sernyak and colleagues found that the prevalence of diabetes in atypical antipsychotic treatments was statistically significantly higher than that of conventional treatment [11]. The authors of this study suggest that it is a causal relationship the Kabinoff et al. suggest the findings only suggest a temporal association [11]. Kabinoff et al. suggest that there is insufficient data from large studies to demonstrate a consistent or significant difference in the risk of insulin resistance during treatment with various atypical antipsychotics [11].
Debate
There has been considerable debate about whether second-generation antipsychotic drugs are better than first-generation antipsychotic drugs.[3] It has been suggested that there is no validity to the term second-generation antipsychotic drugs and that the drugs that currently occupy this category are not identical to each other in mechanism, efficacy, and side-effect profiles:
...the second-generation drugs have no special atypical characteristics that separate them from the typical, or first-generation, antipsychotics. As a group they are no more efficacious, do not improve specific symptoms, have no clearly different side-effect profiles than the first-generation antipsychotics, and are less cost effective. The spurious invention of the atypicals can now be regarded as invention only, cleverly manipulated by the drug industry for marketing purposes and only now being exposed.[15]
Robert Whitaker suggests that the "wonder drug" glow around the second generation psychotropics has long since disappeared. He views the "hyping" of the top-selling atypicals as "one of the more embarrassing episodes in psychiatry's history, as one government study after another failed to find that they were any better than the first-generation anti-psychotics".[16]
See also
References
- ^ Culpepper, L. (2007) A Roadmap to Key Pharmacologic Principles in Using Antipsychotics, Primary Care Companion To The Journal of Association of Medicine and Psychiatry 9(6) 444-454 Retrieved from http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2139919/
- ^ a b c d Horacek, J., Bubenikova-Valeova, V., Kopecek, M., Palenicek, T., Dockery, C., Mohr, P. & Höschl, C. (2006) Mechanism of Action of Atypical Antipsychotic Drugs and the Neurobiology of Schizophrenia, CNS Drugs 20(5) 389-405 Retrieved from Psychology and Behavioral Sciences Collection database.
- ^ a b Stefan Leucht, Caroline Corves, Dieter Arbter, Rolf R Engel, Chunbo Li, John M Davis (January 3, 2009). "Second-generation versus first-generation antipsychotic drugs for schizophrenia: a meta-analysis" (PDF). Lancet. p. 31–41.
{{cite web}}: CS1 maint: multiple names: authors list (link) - ^ Farah A (2005). "Atypicality of atypical antipsychotics". Prim Care Companion J Clin Psychiatry. 7 (6): 268–74. doi:10.4088/PCC.v07n0602. PMC 1324958. PMID 16498489.
- ^ Seeman P (2002). "Atypical antipsychotics: mechanism of action". Can J Psychiatry. 47 (1): 27–38. PMID 11873706.
{{cite journal}}: Unknown parameter|month=ignored (help) - ^ Weiden PJ (2007). "EPS profiles: the atypical antipsychotics are not all the same". J Psychiatr Pract. 13 (1): 13–24. doi:10.1097/00131746-200701000-00003. PMID 17242588.
{{cite journal}}: Unknown parameter|month=ignored (help) - ^ a b c d e f g h i j k l m n o p q r s t u v w Seeman, P. (2002). Atypical Antipsychotics: Mechanism of Action. Canadian Journal of Psychiatry, 47(1), 27. Retrieved from Psychology and Behavioral Sciences Collection database.
- ^ Jones PB, Barnes TR, Davies L; et al. (2006). "Randomized controlled trial of the effect on Quality of Life of second- vs first-generation antipsychotic drugs in schizophrenia: Cost Utility of the Latest Antipsychotic Drugs in Schizophrenia Study (CUtLASS 1)". Arch. Gen. Psychiatry. 63 (10): 1079–87. doi:10.1001/archpsyc.63.10.1079. PMID 17015810.
{{cite journal}}: Explicit use of et al. in:|author=(help)CS1 maint: multiple names: authors list (link) - ^ a b c d e f g h i McKim, W. (2007) Antipsychotics in Drugs and Behavior: An Introduction to Behavioral Pharmacology (pp.241-260). Upper Saddle River, NJ.: Pearson Prentice Hall
- ^ a b Seeman, P. (2002). Atypical Antipsychotics: Mechanism of Action. Canadian Journal of Psychiatry, 47(1), 27. Retrieved from Psychology and Behavioral Sciences Collection database
- ^ a b c d e Kabinoff, G.S., Toalson, P.A., Masur Healey, K., McGuire, H.C. & Hay, D.P. (2003) Metabolic Issues with Atypical Antipsychotics in Primary Care: Dispelling the Myths, Primary Care Companion To The Journal of Association of Medicine and Psychiatry 5(1) 6-14 Retrieved from http://www.ncbi.nlm.nih.gov/pmc/articles/PMC353028/
- ^ Üçok, A& Wolfgang G. (2008). Side Effects of Atypical Antipsychotics: A brief overview. World Psychiatry, 7(1). 58-62 Retrieved from http://www.ncbi.nlm.nih.gov/pmc/articles/ PMC2327229/
- ^ McKim, W. (2007) Psychomotor Stimulants in Drugs and Behavior: An Introduction to Behavioral Pharmacology (pp.241-260). Upper Saddle River, NJ.: Pearson Prentice Hall
- ^ a b c American Diabetes Association; American Psychiatric Association; American
Association of Clinical Endocrinologists; North American Association for the Study of Obesity (2004). "Consensus development conference on antipsychotic drugs and obesity and diabetes". Diabetes Care. 27 (2): 596–601. doi:10.2337/diacare.27.2.596. PMID 14747245.
{{cite journal}}: Unknown parameter|month=ignored (help); line feed character in|author=at position 74 (help)CS1 maint: multiple names: authors list (link) - ^ Peter Tyrer and Tim Kendall (January 3, 2009). "The spurious advance of antipsychotic drug therapy" (PDF). Lancet.
{{cite web}}: Unknown parameter|Vol=ignored (|volume=suggested) (help) - ^ Robert Whitaker (2010). "Anatomy of an Epidemic". Crown. p. 303.
{{cite web}}: Missing or empty|url=(help)